Report Sections

See All Reports

  • HP:0030731: Carcinoma
  • Pneumonia (361) Abnormality of the cardiovascular system (36) Respiratory tract infection (36) Neoplasm (29) Hypoxemia (28) Diabetes mellitus (25) Depressivity (24) Thromboembolism (23) Acute kidney injury (22) Abnormal lung morphology (21) Anosmia (19) Hypertension (18) Abnormality of coagulation (15) Pulmonary embolism (15) Pulmonary fibrosis (15) Stroke (14) Arthritis (14) Interstitial pneumonitis (14) Myocardial infarction (12) Type II diabetes mellitus (12) Deep venous thrombosis (11) Rheumatoid arthritis (10) Leukemia (10) Respiratory distress (10) Low levels of vitamin D (10) Behavioral abnormality (9) Mental deterioration (9) Chronic pain (9) Congestive heart failure (8) Myocarditis (8) Type I diabetes mellitus (8) Sepsis (8) Infertility (7) Abnormality of the liver (7) Lymphopenia (7) Inflammation of the large intestine (7) Pulmonary obstruction (7) Pulmonary insufficiency (7) Immunodeficiency (6) Systemic lupus erythematosus (6) Chronic pulmonary obstruction (6) Abnormality of the gastrointestinal tract (6) Neoplasm of the lung (6) Encephalopathy (5) Obesity (5) Lymphoma (5) Autoimmunity (5) Breast carcinoma (5) Disseminated intravascular coagulation (5) Fatigue (5) Abnormality of the kidney (4) Coronary artery atherosclerosis (4) Cardiac arrest (4) Headache (4) Colon cancer (4) Arrhythmia (4) Carcinoma (4) Hypercoagulability (4) Autistic behavior (3) Seizure (3) Cardiomyopathy (3) Dysphagia (3) Migraine (3) Pulmonary arterial hypertension (3) Asthma (3) Bronchiectasis (3) Neoplasm of the pancreas (3) Psoriasiform dermatitis (3) Attention deficit hyperactivity disorder (3) Cutaneous melanoma (3) Neoplasm of head and neck (3) Pulmonary edema (3) Insomnia (3) Neoplasm of the large intestine (3) Renal insufficiency (2) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Psychosis (2) Autism (2) Dementia (2) Abnormality of the endocrine system (2) Abnormality of the thyroid gland (2) Jaundice (2) Hepatic fibrosis (2) Premature birth (2) Abnormal heart morphology (2) Abnormality of blood and blood-forming tissues (2) Fever (2) Diarrhea (2) Hypothermia (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Encephalitis (2) Obstructive sleep apnea (2) Male infertility (2) Stillbirth (2) Paroxysmal atrial fibrillation (2) Lymphoid leukemia (2) Myeloproliferative disorder (2) Chronic lymphatic leukemia (2) Renal cell carcinoma (2) Multiple myeloma (2) Abnormal anterior horn cell morphology (2) Amyotrophic lateral sclerosis (2) Sleep apnea (2) Cystoid macular edema (2) Hemeralopia (2) Arteritis (2) Chronic kidney disease (2) Cervix cancer (2) Cholangitis (2) Cholangiocarcinoma (2) Myositis (2) Neuroendocrine neoplasm (2) Neoplasm of the rectum (2) Mania (2) Nephritis (1) Menorrhagia (1) Conductive hearing impairment (1) Cataract (1) Amblyopia (1) Periodontitis (1) Abnormality of the nervous system (1) Oligospermia (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Abnormality of the skin (1) Lymphedema (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Spastic diplegia (1) Hemiparesis (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Tachycardia (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Angina pectoris (1) Pancreatitis (1) Premature rupture of membranes (1) Weight loss (1) Thrombocytopenia (1) Autoimmune thrombocytopenia (1) Gastroesophageal reflux (1) Anorexia (1) Esophageal varix (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Hyperkinetic movements (1) Alzheimer disease (1) Increased intracranial pressure (1) Colitis (1) Biliary cirrhosis (1) Hypotension (1) Vascular dilatation (1) Atherosclerosis (1) Osteoarthritis (1) Tachypnea (1) Hypoventilation (1) Myelodysplasia (1) Neoplasm of the liver (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Reduced factor VIII activity (1) Skeletal muscle atrophy (1) Myalgia (1) Muscular dystrophy (1) Neonatal death (1) Increased body weight (1) Neoplasm of the nervous system (1) Malnutrition (1) Thrombophlebitis (1) Ventricular tachycardia (1) Acute myeloid leukemia (1) Dilatation of the cerebral artery (1) Knee osteoarthritis (1) Monoclonal immunoglobulin M proteinemia (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the stomach (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Renal neoplasm (1) Uterine neoplasm (1) Testicular neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Inflammatory abnormality of the skin (1) Placental abruption (1) Postprandial hyperglycemia (1) Endometrial carcinoma (1) Erythroid hypoplasia (1) Asterixis (1) Glioblastoma multiforme (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Morphea (1) Allergy (1) Non-Hodgkin lymphoma (1) Retinal vein occlusion (1) Heart block (1) Dyspareunia (1) Ductal carcinoma in situ (1) Endometriosis (1) Cardiogenic shock (1) Vulvar neoplasm (1) Addictive behavior (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Neoplasm of the central nervous system (1) Abnormality of movement (1) Ulcerative colitis (1) Crohn's disease (1) Endocarditis (1) Toxemia of pregnancy (1) Neoplasm of the larynx (1) Ovarian neoplasm (1) Vaginal neoplasm (1) Cellulitis (1) Bulimia (1) Atelectasis (1) Esophageal neoplasm (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0030731: Carcinoma

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (9)


    Name (Synonyms) Correlation
    drug3892 nasopharyngeal Covid 19 RT-PCR Wiki 0.50
    drug612 COVID-19 convalescent plasma treatment Wiki 0.50
    drug765 Clinical Trial Matching Wiki 0.50
    Name (Synonyms) Correlation
    drug674 CanSwab Wiki 0.50
    drug677 Canakinumab Injection 300mg Wiki 0.50
    drug678 Canakinumab Injection 600mg Wiki 0.50
    drug610 COVID-19 convalescent plasma Wiki 0.22
    drug2687 Questionnaire Administration Wiki 0.14
    drug2532 Placebos Wiki 0.12

    Correlated MeSH Terms (27)


    Name (Synonyms) Correlation
    D002277 Carcinoma NIH 1.00
    D002292 Carcinoma, Renal Cell NIH 0.71
    D002285 Carcinoma, Intraductal, Noninfiltrating NIH 0.50
    Name (Synonyms) Correlation
    D002278 Carcinoma in Situ NIH 0.50
    D016889 Endometrial Neoplasms NIH 0.50
    D004938 Esophageal Neoplasms NIH 0.50
    D013274 Stomach Neoplasms NIH 0.50
    D012878 Skin Neoplasms NIH 0.50
    D044584 Carcinoma, Ductal NIH 0.50
    D018270 Carcinoma, Ductal, Breast NIH 0.50
    D009423 Nervous System Neoplasms NIH 0.50
    D007680 Kidney Neoplasms NIH 0.50
    D016543 Central Nervous System Neoplasms NIH 0.50
    D005909 Glioblastoma NIH 0.50
    D008113 Liver Neoplasms NIH 0.50
    D006528 Carcinoma, Hepatocellular NIH 0.50
    D007822 Laryngeal Neoplasms NIH 0.50
    D013736 Testicular Neoplasms NIH 0.50
    D001943 Breast Neoplasms NIH 0.45
    D002583 Uterine Cervical Neoplasms NIH 0.35
    D012004 Rectal Neoplasms NIH 0.35
    D018281 Cholangiocarcinoma NIH 0.35
    D018358 Neuroendocrine Tumors NIH 0.35
    D010190 Pancreatic Neoplasms NIH 0.29
    D006258 Head and Neck Neoplasms NIH 0.29
    D003110 Colonic Neoplasms NIH 0.25
    D008175 Lung Neoplasms NIH 0.20

    Correlated HPO Terms (23)


    Name (Synonyms) Correlation
    HP:0005584 Renal cell carcinoma HPO 0.71
    HP:0002896 Neoplasm of the liver HPO 0.50
    HP:0008069 Neoplasm of the skin HPO 0.50
    Name (Synonyms) Correlation
    HP:0012114 Endometrial carcinoma HPO 0.50
    HP:0100006 Neoplasm of the central nervous system HPO 0.50
    HP:0010788 Testicular neoplasm HPO 0.50
    HP:0009726 Renal neoplasm HPO 0.50
    HP:0012174 Glioblastoma multiforme HPO 0.50
    HP:0100751 Esophageal neoplasm HPO 0.50
    HP:0004375 Neoplasm of the nervous system HPO 0.50
    HP:0001402 Hepatocellular carcinoma HPO 0.50
    HP:0006753 Neoplasm of the stomach HPO 0.50
    HP:0030075 Ductal carcinoma in situ HPO 0.50
    HP:0100605 Neoplasm of the larynx HPO 0.50
    HP:0003002 Breast carcinoma HPO 0.45
    HP:0100634 Neuroendocrine neoplasm HPO 0.35
    HP:0100743 Neoplasm of the rectum HPO 0.35
    HP:0030153 Cholangiocarcinoma HPO 0.35
    HP:0030079 Cervix cancer HPO 0.35
    HP:0002894 Neoplasm of the pancreas HPO 0.29
    HP:0012288 Neoplasm of head and neck HPO 0.29
    HP:0003003 Colon cancer HPO 0.25
    HP:0100526 Neoplasm of the lung HPO 0.20

    Clinical Trials

    Navigate: Correlations   HPO

    There are 4 clinical trials


    1 TRACERx Renal (TRAcking Renal Cell Carcinoma Evolution Through Therapy (Rx)) CAPTURE: COVID-19 Antiviral Response in a Pan-tumour Immune Study

    TRACERx Renal: This is a translational study, which, aims to develop prognostic and predictive biomarkers for patients with renal cell carcinoma (RCC). CAPTURE Sub-study: Covid-19 antiviral response in a pan-tumour immune monitoring study

    NCT03226886
    Conditions
    1. Renal Cell Carcinoma
    2. Cancer
    3. Healthy Volunteers
    MeSH:Carcinoma Carcinoma, Renal Cell
    HPO:Carcinoma Clear cell renal cell carcinoma Papillary renal cell carcinoma Renal cell carcinoma

    Primary Outcomes

    Description: Outcomes will be quantified using descriptive statistics with the intention of providing hypothesis-generating data for use in future studies.

    Measure: To validate ITH index and WGII as stage and grade independent prognostic markers of progression free survival in patients with ccRCC mutation in a gene of interest

    Time: From trial activation until trial closure approximately 1st September 2023

    Description: Outcomes will be quantified using descriptive statistics

    Measure: CAPTURE Sub-study: Describe the population characteristics between SARS-CoV-2 positive and negative cancer patients

    Time: From sub-study activation until trial closure approximately 2027
    2 SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.

    NCT03452774
    Conditions
    1. Cancer, Metastatic
    2. Cancer
    3. Cancer of Pancreas
    4. Cancer of Liver
    5. Cancer of Stomach
    6. Cancer Liver
    7. Cancer of Rectum
    8. Cancer of Kidney
    9. Cancer of Esophagus
    10. Cancer of Cervix
    11. Cancer of Colon
    12. Cancer of Larynx
    13. Cancer, Lung
    14. Cancer, Breast
    15. Cancer, Advanced
    16. Cancer Prostate
    17. Cancer of Neck
    18. Cancer of Skin
    19. Neuroendocrine Tumors
    20. Carcinoma
    21. Mismatch Repair Deficiency
    22. BRCA Gene Rearrangement
    23. Non Hodgkin Lymphoma
    24. Leukemia
    25. Non Small Cell Lung Cancer
    26. Cholangiocarcinoma
    27. Glioblastoma
    28. Central Nervous System Tumor
    29. Melanoma
    30. Urothelial Carcinoma
    31. Bladder Cancer
    32. Ovarian Cancer
    33. Endometrial Cancer
    34. Testicular Cancer
    35. Breast Cancer
    36. COVID
    Interventions
    1. Other: Clinical Trial Matching
    MeSH:Carcinoma Glioblastoma Endometrial Neoplasms Neuroendocrine Tumors Cholangiocarcinoma Nervous System Neoplasms Central Nervous System Neoplasms Testicular Neoplasms Pancreatic Neoplasms Breast Neoplasms Lung Neoplasms Esophageal Neoplasms Stomach Neoplasms Liver Neoplasms Colonic Neoplasms Uterine Cervical Neoplasms Rectal Neoplasms Kidney Neoplasms Carcinoma, Renal Cell Skin Neoplasms Head and Neck Neoplasms Laryngeal Neoplasms
    HPO:Breast carcinoma Carcinoma Cervical polyp Cervix cancer Cholangiocarcinoma Clear cell renal cell carcinoma Colon cancer Endometrial carcinoma Esophageal neoplasm Glioblastoma multiforme Neoplasm of head and neck Neoplasm of the breast Neoplasm of the central nervous system Neoplasm of the colon Neoplasm of the larynx Neoplasm of the liver Neoplasm of the lung Neoplasm of the nervous system Neoplasm of the pancreas Neoplasm of the rectum Neoplasm of the skin Neoplasm of the stomach Neuroendocrine neoplasm Papillary renal cell carcinoma Renal cell carcinoma Renal neoplasm Testicular neoplasm

    Primary Outcomes

    Description: CTE Accrual

    Measure: Proportion of patients Eligible for CTE versus Actual CTE

    Time: Through study completion, an average of 1 year

    Secondary Outcomes

    Description: OS

    Measure: Impact of CTE on Overall Survival (OS), estimated by Kaplan-Meier and Cox multivariable survival analysis

    Time: 4 years

    Description: PFS

    Measure: Impact of CTE on Progression-Free Survival (PFS), estimated by Kaplan-Meier and Cox multivariable survival analysis

    Time: 4 years

    Description: To identify barriers to accruals to clinical trials, as measured and reported by a questionnaire

    Measure: Identification of Barriers to CTE

    Time: Through study completion, an average of 1 year

    Description: To Analyze Individual Standard of Care Chemotherapy Utilization (nominal), across treatment lines (numeric); data will be combined and aggregated to report chemotherapy utilization rate (%).

    Measure: Real World Data Analytics

    Time: Through study completion, an average of 1 year

    Description: VTB Use Rate

    Measure: Virtual Tumor Board Utilization

    Time: Through study completion, an average of 1 year

    Description: Time to CTE

    Measure: Time from Intervention to Actual CTE (months)

    Time: Through study completion, an average of 1 year
    3 Potential Impact of the COVID -19 Pandemic on Financial Toxicity in Breast Cancer Surgical Patients: The Impact on Out of Pocket Costs, Lost Wages and Economic Strain

    This study investigates the impact of COVID-19 pandemic on out-of-pocket costs, lost wages, and unemployment in patients with breast cancer undergoing breast surgery. Post-mastectomy reconstructive patients are at high risk for financial toxicity (adverse effects of escalating health care cost on well-being). The goal of this study is to collect information about financial costs patients may have as a result of surgical treatment for cancer with or without breast reconstruction and to learn if COVID-19 affects patient costs of breast reconstruction. This may help researchers demonstrate the financial consequences of undergoing breast surgery.

    NCT04169542
    Conditions
    1. Breast Ductal Carcinoma In Situ
    2. COVID-19 Infection
    3. Hereditary Breast Carcinoma
    4. Invasive Breast Carcinoma
    Interventions
    1. Other: Questionnaire Administration
    MeSH:Carcinoma Breast Neoplasms Carcinoma in Situ Carcinoma, Ductal Carcinoma, Intraductal, Noninfiltrating Carcinoma, Ductal, Breast
    HPO:Breast carcinoma Carcinoma Ductal carcinoma in situ Neoplasm of the breast

    Primary Outcomes

    Description: Will be measured by the Comprehensive Score for financial Toxicity questionnaire. Summary statistics including mean, standard deviation, median, and range for continuous variables, and frequency count and percentage for categorical variables will be provided. Various subgroup analyses may occur. In these cases, continuous variables will be compared using the two-sample t-test and categorical variables will be compared using chi-squared test or Fisher's exact test. Multivariate regression analysis will be performed to account for confounding and to increase the robustness of any causal inference.

    Measure: Prevalence of financial toxicity

    Time: Up to 1 year after completion of study

    Secondary Outcomes

    Description: Summary statistics including mean, standard deviation, median, and range for continuous variables, and frequency count and percentage for categorical variables will be provided. Various subgroup analyses may occur. In these cases, continuous variables will be compared using the two sample t-test and categorical variables will be compared using chi-squared test or Fisher's exact test. Multivariate regression analysis will be performed to account for confounding and to increase the robustness of any causal inference.

    Measure: Correlation between economic disruption from coronavirus disease 2019 (COVID-19) and financial toxicity

    Time: Up to 1 year after completion of study

    Description: Will be assessed using the Short Form-12 survey. Summary statistics including mean, standard deviation, median, and range for continuous variables, and frequency count and percentage for categorical variables will be provided. Various subgroup analyses may occur. In these cases, continuous variables will be compared using the two-sample t-test and categorical variables will be compared using chi-squared test or Fisher's exact test. Multivariate regression analysis will be performed to account for confounding and to increase the robustness of any causal inference.

    Measure: Relationship between financial toxicity and patient reported quality of life

    Time: Up to 1 year after completion of study

    Description: Will be assessed using the Breast-Q survey. Summary statistics including mean, standard deviation, median, and range for continuous variables, and frequency count and percentage for categorical variables will be provided. Various subgroup analyses may occur. In these cases, continuous variables will be compared using the two-sample t-test and categorical variables will be compared using chi-squared test or Fisher's exact test. Multivariate regression analysis will be performed to account for confounding and to increase the robustness of any causal inference.

    Measure: Relationship between financial toxicity and patient reported satisfaction with breast reconstruction

    Time: Up to 1 year after completion of study
    4 Impact of COVID-19 Infection in Patients With Hepatocellular Carcinoma: An Ambispective Study Nestled in the CHIEF Cohort

    Since December 2019, a new disease named COVID-19 linked to a new coronavirus, SARS-CoV2 has emerged in China in the city of Wuhan, Hubei province, spreading very quickly to all 5 continents, and responsible for a pandemic. France is the third most affected country in Europe after Italy and Spain. Groups of patients at a higher risk of developing a severe form of COVID-19 have been defined: this include patients with immunosuppressive disease as cancer or patients with advanced cirrhosis of the liver. Coronavirus liver injury had been described with SARS-CoV 1 and MERS-CoV. There is no data on liver damage associated with COVID-19 infection for compensated or decompensated cirrhotic patients. The objectives of this project are to estimate the incidence of COVID-19 in hepatocellular carcinoma population, both hospital and ambulatory, and to study the impact on the frequency of severe forms, the prognosis, but also liver function, and the management of hepatocellular carcinoma, in this context of pandemic

    NCT04367805
    Conditions
    1. Hepatocellular Carcinoma
    2. COVID-19
    Interventions
    1. Diagnostic Test: nasopharyngeal Covid 19 RT-PCR
    MeSH:Carcinoma Carcinoma, Hepatocellular
    HPO:Carcinoma Hepatocellular carcinoma

    Primary Outcomes

    Description: Incidence of COVID-19 infection in patients with hepatocellular carcinoma in France

    Measure: Incidence of COVID-19 infection in patients with hepatocellular carcinoma in France

    Time: 6 months

    HPO Nodes


    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook